Bruno P Coudert
Affiliation: Institut Paoli-Calmettes
- Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trialBruno P Coudert
Department of Oncology, CAC G F Leclerc and IFR 100, Dijon, France
J Clin Oncol 25:2678-84. 2007..Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation...
- Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trialB P Coudert
Oncology, Surgery, Radiology CAC GF Leclerc, Dijon, France
Ann Oncol 17:409-14. 2006..Trastuzumab-based pre-operative systemic (neo-adjuvant) therapy (PST) also appears promising, warranting further investigation...
- It is time for chronotherapy!B Coudert
Centre Georges Francois Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 cedex, Dijon, France
Pathol Biol (Paris) 51:197-200. 2003....
- Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group reportB Coudert
Centre GF Leclerc BP 77980, 21079 Dijon Cedex, France
Eur J Cancer 37:2194-8. 2001....
- It's time for chronotherapy!B Coudert
Centre Georges Francois Leclerc, 1 rue du Professeur Marion, BP 77980, 21079, Dijon Cedex, France
Eur J Cancer 38:S50-3. 2002....
- Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplificationLaurent Arnould
CLCC G F Leclerc and 1FR100, Dijon, France
Clin Cancer Res 13:6404-9. 2007..Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer...
- Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinomaF Vegran
Centre Georges Francois Leclerc, IFR Santé STIC, Dijon Cedex, France
Br J Cancer 101:1357-64. 2009..We examined the ability of microarray analyses to determine the potential markers of pathological complete response (pCR)...
- Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancerS Lizard-Nacol
Laboratory of Molecular Genetics, Centre Georges Francois Leclerc, 1 rue du Professeur Marion, 21034 Dijon Cedex, France
Breast Cancer Res 1:81-7. 1999..Furthermore, a GSTM1 isoenzyme has been positively associated with protective effect against mutagenic drugs, such as alkylating agents and anthracyclines...
- Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analoguesP Fumoleau
Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France
Ann Oncol 18:v9-15. 2007....
- MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patientsS Lizard-Nacol
Centre Georges Francois Leclerc, Dijon, France
Anticancer Res 19:3575-81. 1999....
- Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould
Department of Pathology, Centre G F Leclerc, Dijon 21000, France
Br J Cancer 94:259-67. 2006..These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer...
- Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II studyJ Y Douillard
Centre Rene Gauducheau, Saint Herblain, France
Ann Oncol 16:81-9. 2005..This phase II trial compared docetaxel-cisplatin (DC) with vinorelbine-cisplatin (VC), both as first-line therapy followed by cross-over at progression to single-agent vinorelbine or docetaxel in advanced non-small-cell lung cancer (NSCLC)...
- Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerS Guiu
Department of Oncology, Georges Francois Leclerc Cancer Center, F 21000 Dijon, France
Br J Cancer 103:1335-42. 2010....
- Circadian concepts in normal and neoplastic breastB Coudert
Centre Georges Francois Leclerc, Dijon, France
Chronobiol Int 19:221-35. 2002....
- Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot studyN Isambert
Dept. of Medical Oncology, , Dijon, France
J Exp Clin Cancer Res 20:183-8. 2001..Total dose of cisplatin in hypotonic glucose solution will not exceed 80 mg by cure in a further phase II study...
- Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cellsB Chauffert
INSERM, Unite 252, Faculty of Medicine, Dijon, France
Br J Cancer 56:119-22. 1987..We suggest that amiodarone, which is more efficient and less toxic than verapamil, could be substituted for verapamil in future clinical trials...